# Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

> **NCT01420523** · PHASE2 · TERMINATED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 48 (actual)

## Conditions studied

- Human Immunodeficiency Virus
- Lipohypertrophy

## Interventions

- **DRUG:** Raltegravir-Maraviroc

## Key facts

- **NCT ID:** NCT01420523
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01420523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01420523, "Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01420523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*